Skip to main content

Pemitinib 13.5 mg ( Pemigatinib)

ntroduction

Pemitinib 13.5 mg is identified on this website as a product containing pemigatinib, an oral targeted anticancer medicine belonging to the fibroblast growth factor receptor inhibitor class.

Pemigatinib is designed to inhibit selected FGFR proteins that participate in cellular signaling. These proteins influence several biological processes, including cell growth, differentiation, survival and blood-vessel development.

Certain cancers develop abnormal FGFR signaling through specific genetic alterations. These changes can encourage cancer cells to grow and survive. Pemigatinib targets this abnormal signaling activity and is used in selected patients whose cancers contain the relevant molecular abnormalities.

The stated Pemitinib strength is 13.5 mg. Product-specific information, including its manufacturer, dosage form, packaging and regulatory authorization, should be confirmed through official product documentation.

What Is Pemigatinib?

Pemigatinib is an oral small-molecule kinase inhibitor that selectively targets fibroblast growth factor receptors FGFR1, FGFR2 and FGFR3.

These receptors are part of a family of proteins known as receptor tyrosine kinases. They receive external growth signals and transmit them into cells through intracellular signaling pathways.

Under normal conditions, these pathways regulate:

  • Cellular growth.
  • Cell differentiation.
  • Cell survival.
  • Tissue development.
  • Cellular communication.
  • Formation and maintenance of blood vessels.

When specific genetic abnormalities affect FGFR signaling, these processes may become uncontrolled.

In certain cancers, FGFR gene fusions or rearrangements can create abnormal signaling activity that contributes to malignant cell growth.

Pemigatinib inhibits selected FGFR proteins and interferes with these abnormal signaling pathways.

Classification and Therapeutic Category

ClassificationDescription
Generic namePemigatinib
Brand identifiedPemitinib
Stated strength13.5 mg
Pharmacological classProtein kinase inhibitor
Specific drug classFGFR inhibitor
Therapeutic categoryTargeted anticancer medicine
Molecular targetsFGFR1, FGFR2 and FGFR3
Route of administrationOral
Reference productPEMAZYRE

Pemigatinib is considered a targeted anticancer therapy. It differs from conventional chemotherapy because it acts on selected molecular signaling proteins rather than primarily targeting rapidly dividing cells through broader cytotoxic mechanisms.

Medical Uses of Pemigatinib

Pemigatinib has recognized clinical uses in selected patients with cancers involving particular FGFR genetic abnormalities.

FGFR2-Positive Cholangiocarcinoma

Cholangiocarcinoma is a cancer that develops in the bile ducts. These ducts transport bile from the liver to the digestive system.

Some tumors contain FGFR2 gene fusions or rearrangements. These molecular abnormalities can activate signaling pathways that support cancer development and progression.

Pemigatinib is indicated under U.S. labeling for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma containing an FGFR2 fusion or qualifying rearrangement identified by an FDA-approved test.

The European indication applies to adults with locally advanced or metastatic FGFR2 fusion or rearrangement-positive cholangiocarcinoma that has progressed after at least one previous systemic therapy.

The exact indication and eligibility requirements depend on the relevant country’s regulatory authorization.

FGFR1-Rearranged Myeloid/Lymphoid Neoplasms

Under U.S. prescribing information, pemigatinib is also indicated for adults with relapsed or refractory myeloid/lymphoid neoplasms containing an FGFR1 rearrangement.

These rare diseases involve abnormal blood-forming cells and may affect different blood-cell lineages.

An FGFR1 rearrangement can create abnormal signaling that contributes to disease progression. Pemigatinib inhibits FGFR1 activity and targets this molecular abnormality.

How FGFR Inhibition Works

Fibroblast growth factor receptors receive signals from fibroblast growth factors. Once activated, they trigger intracellular processes that regulate cell growth and survival.

In certain cancers, genetic abnormalities cause the pathway to become abnormally active.

Pemigatinib binds to the kinase domain of selected FGFR proteins and inhibits their activity.

This reduces the transmission of signals involved in abnormal cell growth and survival.

The medicine’s activity is dependent on the relevant biological target being present. This is why molecular testing is important before selecting pemigatinib treatment.

Available Strength and Dosage Form

The Pemitinib product is identified in a stated strength of 13.5 mg.

The established reference product PEMAZYRE is available as oral tablets in 4.5 mg, 9 mg and 13.5 mg strengths.

These different strengths allow healthcare professionals to prescribe the appropriate dose and make adjustments when necessary.

The availability of these strengths for PEMAZYRE should not be interpreted as confirmation that Pemitinib is available in every corresponding strength.

General Administration

Pemigatinib is taken by mouth.

The U.S. reference-product prescribing information describes a 13.5 mg once-daily regimen for qualifying cholangiocarcinoma patients for 14 days, followed by seven days off treatment.

This schedule forms a 21-day cycle.

For qualifying FGFR1-rearranged myeloid/lymphoid neoplasms, the labeled U.S. regimen is 13.5 mg once daily continuously.

Patients should follow the schedule prescribed for their specific condition.

The tablets should be swallowed whole and may be taken with or without food.

Important Precautions

Pemigatinib can produce clinically important adverse reactions.

Hyperphosphatemia is a major concern because FGFR inhibition can affect normal phosphate regulation.

Blood phosphate levels should be monitored throughout treatment.

Ocular toxicity, including retinal pigment epithelial detachment, is another important safety consideration. Eye examinations are recommended before treatment and during therapy.

Patients should promptly report blurred vision, visual floaters, flashes of light or other changes in eyesight.

Additional monitoring may include kidney function, liver function, adverse reactions and potential interactions with other medicines.

Product and Manufacturer Information

The established reference product is PEMAZYRE, developed by Incyte.

Pemitinib is the brand name identified for this website. The specific manufacturer, legal brand owner and marketing authorization holder must be verified from the actual product packaging and official documentation.

It is important not to confuse the developer of pemigatinib with the manufacturer of a separately branded product.

Conclusion

Pemitinib 13.5 mg is presented as a pemigatinib-containing product intended for information about a targeted anticancer medicine.

Pemigatinib works by inhibiting selected FGFR proteins and has recognized applications in specific molecularly defined cancer populations.

Its use requires appropriate molecular testing, professional prescribing and ongoing monitoring.

Patients should obtain individualized treatment guidance from a qualified oncology or hematology specialist.